Physician profile
Richard Tom
NPI 1952396517
$3,204.55
in general payments reported to CMS, 2019-2025
32 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $212 · 2021: $520 · 2022: $850 · 2023: $590 · 2024: $495 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,219.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $771.07 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $342.03 | 2020-2025 | |
| Hologic Sales and Service, LLC | $244.38 | 2019-2025 | Aptima, Coolseal Generator, Acessa Provu System |
| Myovant Sciences INC. | $174.18 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $173.85 | 2021-2025 | Gardasil 9, Gardasil |
| Coopersurgical, INC. | $160.50 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Aspira Women'S Health INC | $159.29 | 2021-2024 | Ova1 |
| Mylan Pharmaceuticals INC. | $129.59 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $115.43 | 2022-2023 | |
| Exeltis, USA INC. | $107.74 | 2022-2024 | Slynd |
| Organon LLC | $103.05 | 2022-2024 | Nexplanon |
| Therapeuticsmd, INC. | $72.33 | 2021-2022 | |
| Agile Therapeutics, INC. | $69.53 | 2021-2022 | |
| Pfizer INC. | $61.55 | 2021-2024 | |
| Amag Pharmaceuticals, INC. | $50.81 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $47.90 | 2023 | Myfembree |
| Astellas Pharma US INC | $45.89 | 2024 | Veozah |
| Shield Therapeutics INC | $42.70 | 2023-2024 | Accrufer |
| Vertex Pharmaceuticals Incorporated | $41.80 | 2024-2025 | |
| Lupin INC. | $41.63 | 2020 | |
| Amgen INC. | $38.80 | 2022-2023 | Prolia, Evenity |
| Kerecis Limited | $26.16 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Biogen, INC. | $25.78 | 2024 | Zurzuvae |
| Convatec INC. | $25.73 | 2019 | |
| Mimedx Group, INC. | $19.13 | 2025 | |
| Gynesonics, INC. | $17.66 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Scynexis, INC. | $17.62 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $17.47 | 2024 | Exparel |
| Sanofi Pasteur INC. | $17.06 | 2024 | |
| Dysis Medical, INC. | $16.21 | 2020 | |
| Meditrina | $14.34 | 2023 | |
| Evofem Biosciences, INC. | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.